Search Results - "Pyadushkina, E"

Fixed Dose Combinations of Nucleoside Reverse Transcriptase Inhibitor for Naïve Patient with Hiv Infection in Russia: Cost Comparison Analysis by Ignatyeva, V, Pyadushkina, E, Omelyanovsky, V.V

Get full text

Economic Evaluation Of Various Strategies For Antiviral Therapy For Previously Treated Patients With Chronic Hcv Genotipe 1 Infection by Avxentyeva, M, Pyadushkina, E, Derkach, E.V

Get full text

Analysis of social and economic aspects of using prolonged forms of opioid analgesics for the treatment of chronic pain syndrome in cancer patients by Pyadushkina, E. A., Derkach, E. V., Palekhov, A. V.

“…Background . The therapy of chronic pain in cancer patients is a highly topical issue for the modern health care system. Intense pain syndrome involves the…”
Get full text

Cost-Effectiveness Analysis Of Antiviral Pharmacotherapies For Treatment Of Chronic Hepatitis C Virus Infection In Russia by Pyadushkina, E, Avxentyeva, M, Omelyanovsky, V.V, Treur, M, Westerhout, K.Y

Get full text

Cost-Minimization Analysis of Maraviroc Versus Darunavir Raltegravir and Enfuvirtide for CCR5-Tropic Treatment-Experienced Patients with HIV Infection in Russia by Pyadushkina, E, Omelyanovsky, V, Avxentyeva, M, Rebrova, O, Goryaynov, S

Get full text

Pharmacoeconomic Evaluation of the Fixed-Dose Combination of Abacavir/Lamivudine in the Antiretroviral Therapy of Naïve HIV Infected Patients in Russia by Pyadushkina, E, Omelyanovsky, V, Avxentyeva, M, Rebrova, O, Andreeva, N

Get full text

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS by Pyadushkina, E. A.

“…Aims of the study: to assess health care costs of the use of biological agents (vedolizumab and various TNF-α inhibitors) in adult patients with moderate to…”
Get full text

CLINICAL AND ECONOMIC ANALYSIS OF ALTERNATIVE SCHEMES OF ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C GENOTYPE 1 IN PATIENTS WHO DID NOT ANSWER TO THE PRIOR THERAPY, IN THE RUSSIAN FEDERATION by Pyadushkina, E V, Avxentyeva, M V, Omelyanovsky, V V, Khachatryan, G R

“…We conducted clinical and economic analysis of the protease inhibitor simeprevir versus currently available in Russia protease inhibitors (boceprevir and…”
Get more information

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system by Pyadushkina, E. A., Derkach, E. V., Frolov, M. Yu, Rogov, V. A., Salasyuk, A. S.

“…Objective : to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of…”
Get full text

Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting by Pyadushkina, E. A., Derkach, E. V., Ignatyeva, V. I., Yagnenkova, E. E., Klitochenko, T. Yu, Shelekhova, T. V., Levanov, A. N.

“…Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma…”
Get full text

CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY by Pyadushkina, E. A., Frolov, M. Yu

“…Aims of study: 1) development of a model for forecasting of impact of Lacosamide administration for antiseizure therapy of local convulsions in patients, who…”
Get full text

The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups by Derkach, E. V., Pyadushkina, E. A., Avxentyeva, M. V., Boyarskaya, T. V., Yagnenkova, E. E., Mokrova, A. S., Maryanyan, M. M.

“…Diagnosis-Related Groups (DRG) for the payment for biological therapy were created at the stage of the pilot project and their coefficients of input intensity…”
Get full text

PCN173 - COST-EFFECTIVENESS OF NEW TRIPLET COMBINATIONS WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA by Pyadushkina, E., Derkach, E.V.

Get full text

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY by Avxentyev, N. A., Derkach, E. V., Pyadushkina, E. A., Ter-Ovanesov, M. D.

“…Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further lines therapy options include anti-EGFR therapy, eligible for…”
Get full text

PIN40 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA by Ignatyeva, V., Pyadushkina, E., Derkach, E.V.

Get full text

PCN73 - BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA by Pyadushkina, E., Derkach, E.V., Boyarskaya, T.

Get full text

Tofacitinib in Adult Patients with Active Rheumatoid Arthritis: Budget Impact Analysis by Pyadushkina, E, Derkach, EV

“…BACKGROUND: Tofacitinib is a new drug in Russian pharmaceutical market indicated for adult patients with active rheumatoid arthritis (RA) and an inadequate…”
Get full text

PMS18 - Tofacitinib in Adult Patients with Active Rheumatoid Arthritis: Budget Impact Analysis by Pyadushkina, E, Derkach, EV

Get full text

Cost-Effectiveness of Vedolizumab for the Treatment of Adult Patients with Moderately-to-Severely Active Ulcerative Colitis in Russia by Pyadushkina, E, Derkach, EV

“…BACKGROUND: Vedolizumab is one of the biologic drugs recommended by current clinical guidelines for the treatment of moderately-to-severely active ulcerative…”
Get full text

PGI20 - Cost-Effectiveness of Vedolizumab for the Treatment of Adult Patients with Moderately-to-Severely Active Ulcerative Colitis in Russia by Pyadushkina, E, Derkach, EV

Get full text